The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome.
OBJECTIVE
To investigate the effects of oral natural micronized P on hormonal and metabolic parameters in patients with polycystic ovary syndrome (PCOS) and to answer the clinical question whether induction of withdrawal bleeding is a necessity for the comparison of hormonal and metabolic data in subjects with PCOS.


METHODS
Prospective clinical study.


METHODS
Academic medical center.


METHODS
Twenty-eight reproductive-aged women with PCOS.


METHODS
Blood sampling was collected at baseline, after 7 days of oral natural micronized P (200 mg) administration, and after withdrawal bleeding. At these three stages hormonal parameters and homeostasis assessment model (HOMA-IR) index were assessed in all patients.


RESULTS
Oral natural micronized P administration did not alter significantly insulin sensitivity index and androgen levels; however, LH was decreased when postbleeding values were compared to baseline. Nevertheless, after oral natural micronized P administration, P and 17alpha-hydroxyprogesterone (17-OHP) concentrations were increased, and HOMA-IR was decreased, whereas androgens levels were not altered, in comparison with baseline.


CONCLUSIONS
The induction of withdrawal bleeding, with this regimen, does not appear to be a necessity for the assessment of hormonal and metabolic profile in anovulatory women with PCOS.
Livadas
Sarantis
S
First Department of Medicine, Endocrine Section, University of Athens Medical School, Athens, Greece.
Boutzios
Georgios
G
Economou
Fragiskos
F
Alexandraki
Krystallenia
K
Xyrafis
Xenofon
X
Christou
Maria
M
Zerva
Aristea
A
Karachalios
Athanasios
A
Tantalaki
Evangelia
E
Diamanti-Kandarakis
Evanthia
E
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D011374:Progesterone / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry*; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D011374:Progesterone; D007986:Luteinizing Hormone